BYSI - BeyondSpring's Plinabulin Offers Multiple Roadmaps (Via Multiple Geographies) To Becoming A Blockbuster
Our analysis concludes BeyondSpring Inc. (BYSI) offers investors exponential gain potential if BYSI's first NDA submitted in China and anticipated NDA submission in the United States are approved. This is because BYSI's product, Plinabulin, has estimated peak revenue potential in the billions (here in the US and in China), as the new standard of care in managing chemotherapy induced neutropenia, while BYSI's market cap is approximately $350MM. BYSI submitted a rolling NDA in China in Q1 2020 because Phase 3 primary endpoints were met at interim analysis. Should Plinabulin's Phase 3 endpoints be